Currently, there are no interventional treatment modalities that ameliorate mild traumatic brain injury: Post-concussion syndrome (PCS), or chronic concussive syndrome (CCS). We are focused on developing personalized therapeutic treatments to mitigate the constellation of symptoms unique to each individual suffering from PCS. By harnessing each body's intrinsic mechanisms, we are developing individual treatments as unique as you are. #americancryostem, #mTBI, #PCS, #stemcells, #autologoustreatments, #healingpower, #bioinsurance, #mesenchymalstemcells, #MSCs
Advancements in Traumatic Brain Injury (TBI) treatment drugs herald a new era in healthcare, as innovative therapies emerge, offering hope and improved patient outcomes. The evolving TBI drug market showcases a commitment to research and development, steering towards personalized and targeted approaches, promising enhanced recovery and quality of life. As the therapeutics innovation continues to unravel the complexities of brain injuries, a wave of transformative treatments is reshaping the landscape, signaling a brighter future for those affected by TBI. Some of the major pharma and biotech giants such as Life Molecular Imaging, Hope Biosciences, Merz Therapeutics, vasopharm GmbH, Pinteon Therapeutics, Omniscient Neurotechnology (o8t), Pfizer, Supernus Pharmaceuticals, Inc., Solstice Neurosciences, Ipsen, American CryoStem Corporation, and others are actively developing novel Traumatic Brain Injury therapies. Learn more about the key factors driving the Traumatic Brain Injury (TBI) market outlook: https://lnkd.in/gPP7bS_u #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast